PubMed Health⌕ Search

Biomedical subjects

V Santinelli

Publications and source records attributed to V Santinelli.

At least 55 records · Page 3Linked to original sources
PubMed1982

Further observations on the electrophysiologic effects of oral amiodarone therapy.

A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities. His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals (40 and 100 msec, respectively). Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay. Amiodarone should be used with caution during long-term oral therapy in patients with or without clear intraventricular conduction defects.

Adult↗
PubMed1982

[Mexiletine in the treatment of lidocaine-resistant ventricular tachycardia. Preliminary results].

Intravenous mexiletine (3 mg/Kg as bolus) was given to 7 patients with sustained ventricular tachycardia. Previous lidocaine administration in standard doses failed to suppress ventricular tachycardia. Mexiletine successfully suppressed the episodes of ventricular tachycardia in 6 of the 7 patients at a dose of 250 mg. Minimal non-cardiac toxicity occurred after mexiletine administration in the majority of patients. Mexiletine appears to be a promising alternative to lidocaine in the management of ventricular arrhythmias.

Drug Resistance↗
PubMed1980

Effects of intravenous disopyramide on myocardial function in patients with different degrees of cardiac failure.

The effects of intravenous disopyramide phosphate on myocardial function were evaluated by non-invasive indices of cardiac performance (systolic time intervals, STI) in 15 patients with atherosclerotic heart disease and different degrees of cardiac failure. Disopyramide (1.5 mg/Kg) was given intravenously over a period of 5 min. This drug induced in patients in I-II classes of NYHA a significant decrease of LVETc, while PEP, ICT, and PEP/LVET ratio rose significantly. STI were affected much more markedly in patients in III-IV classes of NYHA. Particularly affected were contractility indices (PEP, ICT, PEP/LVET), which were reduced significantly more in patients in III-IV classes as compares to patient in I-II classes. In contrast, LVETc, which correlates to stroke volume and cardiac output, was similarly worsened by the drug in the 2 groups of patients. Therefore, this study shows that disopyramide has relevant depressant effects on myocardial performance, simultaneously reducing stroke volume and contractility, and that the effect on contractility is more marked in patients with severe left ventricular impairment.

Arrhythmias, Cardiac↗
PubMed1979

[The effects of intravenous mexiletine on cardiac performance (author's transl)].

The effects of intravenous Mexiletine (Kö1173) on cardiac performance has been studied in 20 patients affected by myocardiosclerosis (10 patients were classified in the 1st or 2nd NYHA classes, 10 cases in the 3rd or 4th ones. Mexiletine (1.5 mg/Kg) was given intravenously over a period of 1 minute. The effect on myocardial function has been evaluated by means of the systolic time intervals (STI). The drug caused non-significant changes of the left ventricular ejection time (LVET); on the contrary it caused a significant increases of the pre-ejection period (PEP), isometric contraction time (ICT) and the PEP/LVET ratio. These alteration became evident after 5--10 minutes and disappeared about 30 minutes after administration of the drug.

Adult↗
PubMed1979

[Clinical and hemodynamic effects of disopyramide phosphate administered i.v. in cardiopathic subjects (author's transl)].

The antiarrhythmic action of disopyramide (1.5 mg/Kg) administered i.v. as a bolus was assessed in 30 patients with ischemic heart disease and different arrhythmias. In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias. The hemodynamic effects of the same dose of disopyramide were evaluated in other 17 patients, 9 of which in I-II class NYHA and 8 in III-IV class. We used STI's as parameters of cardiac performance. In all patients following the injection of disopyramide, a significant increase of PEP, ICT and PEP/LVET ratio and a significant decrease of LVETc were observed. Thus, the disopyramide impaired cardiac performance and its effect appeared more evident in patients in III-IV class NYHA. In conclusion, disopyramide showed to be effective in interrupting different arrhythmias; however, its depressant action on cardiac performance suggests that caution should be used in patients with severely impaired myocardial function.

Adult↗